GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aerovate Therapeutics Inc (NAS:AVTE) » Definitions » FCF Yield %

AVTE (Aerovate Therapeutics) FCF Yield % : -101.36 (As of Dec. 13, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aerovate Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Aerovate Therapeutics's Trailing 12-Month Free Cash Flow is $-75.01 Mil, and Market Cap is $73.14 Mil. Therefore, Aerovate Therapeutics's FCF Yield % for today is -101.36%.

The historical rank and industry rank for Aerovate Therapeutics's FCF Yield % or its related term are showing as below:

AVTE' s FCF Yield % Range Over the Past 10 Years
Min: -191.93   Med: 0   Max: 0
Current: -101.36


AVTE's FCF Yield % is ranked worse than
84.54% of 1507 companies
in the Biotechnology industry
Industry Median: -13.02 vs AVTE: -101.36

Aerovate Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.


Aerovate Therapeutics FCF Yield % Historical Data

The historical data trend for Aerovate Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aerovate Therapeutics FCF Yield % Chart

Aerovate Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
FCF Yield %
- - -9.58 -5.43 -9.06

Aerovate Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.67 -9.46 -11.48 -170.63 -106.36

Competitive Comparison of Aerovate Therapeutics's FCF Yield %

For the Biotechnology subindustry, Aerovate Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aerovate Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aerovate Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Aerovate Therapeutics's FCF Yield % falls into.



Aerovate Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Aerovate Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-56.92 / 628.269901
=-9.06%

Aerovate Therapeutics's annualized FCF Yield % for the quarter that ended in Sep. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-16.043 * 4 / 60.333493
=-106.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aerovate Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Aerovate Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of Aerovate Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aerovate Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
930 Winter Street, Suite M-500, Waltham, MA, USA, 02451
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
Executives
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
George A Eldridge officer: See Remarks C/O TARGANTA THERAPEUTICS CORPORATION, 222 THIRD STREET SUITE 2300, CAMBRIDGE MA 02142
Marinus Verwijs officer: SENIOR VICE PRESIDENT, CMC C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Hunter Gillies officer: Chief Medical Officer C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Timothy P Noyes director, officer: Chief Executive Officer 1365 MAIN STREET, WALTHAM MA 02451
Benjamin T Dake officer: See Remarks C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
David S. Grayzel director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Ralph Niven officer: Chief Development Officer C/O AEROVATE THERAPEUTICS, INC., 200 BERKELEY STREET, FLOOR 18, BOSTON MA 02116
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Timothy Pigot officer: Chief Commercial Officer AEROVATE THERAPEUTICS, INC., 930 WINTER STREET, SUITE M-500, WALTHAM MA 02451
Donald J Santel director 4362 24TH STREET, SAN FRANCISCO CA 94114
Allison Dorval director C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116